DOCSLIB.ORG

Investigation of the Hsp90 C-Terminal Binding Site, Novel Inhibitors and Isoform-Dependent Client Proteins

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Investigation of the Hsp90 C-Terminal Binding Site, Novel Inhibitors and Isoform-Dependent Client Proteins Investigation of the Hsp90 C-terminal Binding Site, Novel Inhibitors and Isoform-Dependent Client Proteins By Laura B. Peterson Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. ________________________________ Brian S. J. Blagg, Ph.D. Chairperson ________________________________ Thomas E. Prisinzano, Ph.D. ________________________________ Michael F. Rafferty, Ph.D. ________________________________ Jon A. Tunge, Ph.D. ________________________________ Rick T. Dobrowsky, Ph.D. Date Defended: May 30th, 2012 The Dissertation Committee for Laura B. Peterson certifies that this is the approved version of the following dissertation: Investigation of the Hsp90 C-terminal Binding Site, Novel Inhibitors and Isoform-Dependent Client Proteins ________________________________ Brian S. J. Blagg, Ph.D. Chairperson Date approved: June 1st, 2012 ii Abstract The heat shock proteins represent an important class of pro-survival proteins that are intimately involved in cell survival, adaptation to cellular stress, and protein management. Heat shock protein 90 kDa (Hsp90) is a molecular chaperone responsible for the post-translational maturation of nascent polypeptides. Many of the Hsp90-dependent client proteins are involved in oncogenic processes, and accordingly, Hsp90 has emerged as a promising target for anti-cancer therapies. Unfortunately, the clinical evaluation of Hsp90 inhibitors has been met with dosing, scheduling, and toxicity issues. The Hsp90 inhibitors that have reached clinical trials bind to the Hsp90 N-terminal ATP-binding site and demonstrate pan-Hsp90 inhibition, as they bind to and inhibit all four human Hsp90 isoforms. This characteristic may rationalize the undesired toxicities related to Hsp90 inhibition. Interestingly, the identification and characterization of isoform specific client proteins has not been extensively explored. In addition, N-terminal Hsp90 inhibition results in the induction of the heat shock response, whereby the expression of Hsp90 and other heat shock proteins is induced. This attribute of N-terminal inhibitors results in the clinically observed dosing and scheduling detriments as levels of Hsp90 increase with administration of the drug. Described herein is the design, synthesis and biological evaluation of novel Hsp90 inhibitors that avoid the above mentioned therapeutic liabilities of currently known Hsp90 inhibitors. The identification and characterization of an Hsp90-isoform dependent client protein and an Hsp90-isoform selective inhibitor is also presented. iii Acknowledgements For me, graduate school provided a chance for personal growth and a platform to challenge myself. Without the many mentors, family members, and friends I have made and maintained while at the University of Kansas, this experience would not have been nearly as fulfilling. Those people deserve my recognition and gratitude. First, thank you to my advisor, Dr. Brian S. J. Blagg. Brian was a constant source of knowledge, motivation, and inspiration and he helped me to grow as a scientist. I would also like to thank the other members of the Blagg Laboratory of all who greatly influenced my graduate career. Specifically, Adam Duerfeldt was an amazing colleague and friend who engaged in insightful discussions and generally made my time here more enjoyable. Outside of the Blagg Laboratory, thank you to Dr. Thomas Prisinzano and his lab members, all of whom greatly impacted my graduate school career. I would also like to thank Chrisostomos Prodromou for mentoring me during my research rotation at the Institute of Cancer Research. Besides support from my KU network, I would never be where I am today without my family. To my Mom and Dad who had high expectations for me and never let me settle for mediocrity and to my brother who is a great role model, friend, and my ultimate competition – thank you! Lastly, to my future husband, Alexander Grenning - who is my best friend and always pushes me to be better, his support and friendship means a tremendous amount to me. In addition to the amazing people I have had the opportunity to meet and work with over the last five years, I must thank the Department of Medicinal Chemistry, the Smissman Fellowship, the NIH Dynamic Aspects of Chemical Biology Training Grant, and the American Chemical Society Division of Medicinal Chemistry Pre-doctoral Fellowship for financial support. iv Table of Contents: Chapter I Introduction to Hsp90 Structure, Function, and Inhibition I. Introduction ..................................................................................................................................1 II. Heat Shock Protein 90 .................................................................................................................1 A. Hsp90 Structure......................................................................................................................2 B. Hsp90 Function ......................................................................................................................4 III. Heat Shock Protein 90 Inhibitors ...............................................................................................9 A. Therapeutic Opportunities ....................................................................................................10 A.1. Cancer ..........................................................................................................................10 A.2. Neurodegenerative Diseases ........................................................................................12 B. N-Terminal Inhibitors ..........................................................................................................16 C. C-Terminal Inhibitors ...........................................................................................................18 D. Other Inhibitors ....................................................................................................................19 IV. Clinical Detriments and Liabilities of Hsp90 Inhibition .........................................................20 A. Heat Shock Induction ...........................................................................................................20 B. Toxicities ..............................................................................................................................22 C. Other Considerations ............................................................................................................23 V. Conclusions and Future Directions of Hsp90 Inhibition ..........................................................24 VI. References................................................................................................................................25 Chapter II Exploration of the Hsp90 C-terminal Binding Site I. Introduction ................................................................................................................................37 A. C-terminal Domain Structure ...............................................................................................38 B. C-terminal Domain Function and Modulation .....................................................................41 v II. Development of a CoMFA for Hsp90 C-Terminal Inhibitors...................................................45 III. Development of a C-terminal Binding Site Model ..................................................................50 A. Identification of the Novobiocin Binding Site in Hsp90’s C-terminal Domain ..................50 B. Modeling of Novobiocin’s Conformation ............................................................................52 C. Modeling of the Hsp90 Novobiocin Binding Site ................................................................53 D. Correlation to Observed Effects Resulting from C-Terminal Inhibition .............................57 IV. Synthesis and Evaluation of a Series of Triazole Containing Novobiocin Analogues............60 A. Rationale for the Development of Triazole Containing Novobiocin Analogues .................60 B. Synthesis of Triazole Containing Novobiocin Analogues ...................................................61 C. Biological Evaluation of Triazole Containing Novobiocin Analogues ...............................63 V. Conclusions and Future Work...................................................................................................66 A. Structure Based Drug Design of Novel C-terminal Inhibitors .............................................67 B. Progress towards a C-terminal Inhibitor Co-Crystal Structure ............................................68 VI. Materials and Methods ............................................................................................................69 A. Development of a CoMFA for Hsp90 C-Terminal Inhibitors .............................................69 B. Identification of the Novobiocin Binding Site in Hsp90’s C-terminal Domain ..................75 C. Synthesis and Evaluation of a Series of Triazole Containing Novobiocin Analogues ........76 VII. References ..............................................................................................................................99 Chapter III Biological Evaluation of Isoform Selective Hsp90 Inhibitors and Characterization of Isoform Dependent Client Proteins I. Introduction ..............................................................................................................................104
Load more

Recommended publications
  • Yichen – Structure and Allostery of the Chaperonin Groel. Allosteric
    Literature Lunch 5-1-13 Yichen – J Mol Biol. 2013 May 13;425(9):1476-87. doi: 10.1016/j.jmb.2012.11.028. Epub 2012 Nov 24. Structure and Allostery of the Chaperonin GroEL. Saibil HR, Fenton WA, Clare DK, Horwich AL. Source Crystallography and Institute of Structural and Molecular Biology, Birkbeck College London, Malet Street, London WC1E 7HX, UK. Abstract Chaperonins are intricate allosteric machines formed of two back-to-back, stacked rings of subunits presenting end cavities lined with hydrophobic binding sites for nonnative polypeptides. Once bound, substrates are subjected to forceful, concerted movements that result in their ejection from the binding surface and simultaneous encapsulation inside a hydrophilic chamber that favors their folding. Here, we review the allosteric machine movements that are choreographed by ATP binding, which triggers concerted tilting and twisting of subunit domains. These movements distort the ring of hydrophobic binding sites and split it apart, potentially unfolding the multiply bound substrate. Then, GroES binding is accompanied by a 100° twist of the binding domains that removes the hydrophobic sites from the cavity lining and forms the folding chamber. ATP hydrolysis is not needed for a single round of binding and encapsulation but is necessary to allow the next round of ATP binding in the opposite ring. It is this remote ATP binding that triggers dismantling of the folding chamber and release of the encapsulated substrate, whether folded or not. The basis for these ordered actions is an elegant system of nested cooperativity of the ATPase machinery. ATP binds to a ring with positive cooperativity, and movements of the interlinked subunit domains are concerted.
    [Show full text]
  • Functional and Physical Interaction Between Yeast Hsp90 and Hsp70
    Functional and physical interaction between yeast PNAS PLUS Hsp90 and Hsp70 Andrea N. Kravatsa, Joel R. Hoskinsa, Michael Reidyb, Jill L. Johnsonc, Shannon M. Doylea, Olivier Genesta,1, Daniel C. Masisonb, and Sue Wicknera,2 aLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; bLaboratory of Biochemistry and Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892; and cDepartment of Biological Sciences, University of Idaho, Moscow, ID 83844 Contributed by Sue Wickner, January 25, 2018 (sent for review November 17, 2017; reviewed by Daniel N. A. Bolon and Jeffrey L. Brodsky) Heat shock protein 90 (Hsp90) is a highly conserved ATP-dependent changes in response to ATP binding, hydrolysis, and ADP release molecular chaperone that is essential in eukaryotes. It is required for (1,3,6,14–16). In the absence of ATP, the Hsp90 dimer acquires the activation and stabilization of more than 200 client proteins, an open, V-shaped structure such that the protomers interact via including many kinases and steroid hormone receptors involved in the C-terminal dimerization domain (16). When ATP is bound, the cell-signaling pathways. Hsp90 chaperone activity requires collabo- protein takes on a closed conformation with the two N-domains of ration with a subset of the many Hsp90 cochaperones, including the the dimer interacting and a portion of the N-domain, the “lid,” Hsp70 chaperone. In higher eukaryotes, the collaboration between closing over the nucleotide in each protomer (16, 17). Additional Hsp90 and Hsp70 is indirect and involves Hop, a cochaperone that conformational changes occur upon ATP hydrolysis, resulting in a interacts with both Hsp90 and Hsp70.
    [Show full text]
  • Identification and Characterization of Three Heat Shock Protein 90
    G C A T T A C G G C A T genes Article Identification and Characterization of Three Heat Shock Protein 90 (Hsp90) Homologs in the Brown Planthopper Xuan Chen 1,2, Ze-Dong Li 1, Yi-Ting Dai 1, Ming-Xing Jiang 1,* and Chuan-Xi Zhang 1,2,* 1 State Key Laboratory of Rice Biology and Ministry of Agriculture Key Laboratory of Agricultural Entomology, Institute of Insect Science, Zhejiang University, Hangzhou 310058, China; [email protected] (X.C.); [email protected] (Z.-D.L.); [email protected] (Y.-T.D.) 2 State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-Products, Key Laboratory of Biotechnology in Plant Protection of MOA of China and Zhejiang Province, Institute of Plant Virology, Ningbo University, Ningbo 315211, China * Correspondence: [email protected] (M.-X.J.); [email protected] (C.-X.Z.) Received: 9 August 2020; Accepted: 10 September 2020; Published: 12 September 2020 Abstract: Hsp90 (heat shock protein 90) chaperone machinery is considered to be a key regulator of proteostasis under both physiological and stress growth conditions in eukaryotic cells. The high conservation of both the sequence and function of Hsp90 allows for the utilization of various species to explore new phenotypes and mechanisms. In this study, three Hsp90 homologs were identified in the brown planthopper (BPH), Nilaparvata lugens: cytosolic NlHsp90, endoplasmic reticulum (ER) NlGRP94 and mitochondrial NlTRAP1. Sequence analysis and phylogenetic construction showed that these proteins belonged to distinct classes consistent with the predicted localization and suggested an evolutionary relationship between NlTRAP1 and bacterial HtpG (high-temperature protein G).
    [Show full text]
  • Heat Shock Protein 27 Is Involved in SUMO-2&Sol
    Oncogene (2009) 28, 3332–3344 & 2009 Macmillan Publishers Limited All rights reserved 0950-9232/09 $32.00 www.nature.com/onc ORIGINAL ARTICLE Heat shock protein 27 is involved in SUMO-2/3 modification of heat shock factor 1 and thereby modulates the transcription factor activity M Brunet Simioni1,2, A De Thonel1,2, A Hammann1,2, AL Joly1,2, G Bossis3,4,5, E Fourmaux1, A Bouchot1, J Landry6, M Piechaczyk3,4,5 and C Garrido1,2,7 1INSERM U866, Dijon, France; 2Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, Burgundy, France; 3Institut de Ge´ne´tique Mole´culaire UMR 5535 CNRS, Montpellier cedex 5, France; 4Universite´ Montpellier 2, Montpellier cedex 5, France; 5Universite´ Montpellier 1, Montpellier cedex 2, France; 6Centre de Recherche en Cance´rologie et De´partement de Me´decine, Universite´ Laval, Quebec City, Que´bec, Canada and 7CHU Dijon BP1542, Dijon, France Heat shock protein 27 (HSP27) accumulates in stressed otherwise lethal conditions. This stress response is cells and helps them to survive adverse conditions. We have universal and is very well conserved through evolution. already shown that HSP27 has a function in the Two of the most stress-inducible HSPs are HSP70 and ubiquitination process that is modulated by its oligomeriza- HSP27. Although HSP70 is an ATP-dependent chaper- tion/phosphorylation status. Here, we show that HSP27 is one induced early after stress and is involved in the also involved in protein sumoylation, a ubiquitination- correct folding of proteins, HSP27 is a late inducible related process. HSP27 increases the number of cell HSP whose main chaperone activity is to inhibit protein proteins modified by small ubiquitin-like modifier aggregation in an ATP-independent manner (Garrido (SUMO)-2/3 but this effect shows some selectivity as it et al., 2006).
    [Show full text]
  • HSP90 Interacts with the Fibronectin N-Terminal Domains and Increases Matrix Formation
    cells Article HSP90 Interacts with the Fibronectin N-terminal Domains and Increases Matrix Formation Abir Chakraborty 1 , Natasha Marie-Eraine Boel 1 and Adrienne Lesley Edkins 1,2,* 1 Biomedical Biotechnology Research Unit, Department of Biochemistry and Microbiology, Rhodes University, Grahamstown 6140, South Africa; [email protected] (A.C.); [email protected] (N.M.-E.B.) 2 Centre for Chemico- and Biomedicinal Research, Rhodes University, Grahamstown 6140, South Africa * Correspondence: [email protected] Received: 20 December 2019; Accepted: 18 January 2020; Published: 22 January 2020 Abstract: Heat shock protein 90 (HSP90) is an evolutionarily conserved chaperone protein that controls the function and stability of a wide range of cellular client proteins. Fibronectin (FN) is an extracellular client protein of HSP90, and exogenous HSP90 or inhibitors of HSP90 alter the morphology of the extracellular matrix. Here, we further characterized the HSP90 and FN interaction. FN bound to the M domain of HSP90 and interacted with both the open and closed HSP90 conformations; and the interaction was reduced in the presence of sodium molybdate. HSP90 interacted with the N-terminal regions of FN, which are known to be important for matrix assembly. The highest affinity interaction was with the 30-kDa (heparin-binding) FN fragment, which also showed the greatest colocalization in cells and accommodated both HSP90 and heparin in the complex. The strength of interaction with HSP90 was influenced by the inherent stability of the FN fragments, together with the type of motif, where HSP90 preferentially bound the type-I FN repeat over the type-II repeat. Exogenous extracellular HSP90 led to increased incorporation of both full-length and 70-kDa fragments of FN into fibrils.
    [Show full text]
  • Heat Shock Protein 27 Interacts with Vimentin and Prevents Insolubilization of Vimentin Subunits Induced by Cadmium
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 37, No. 5, 427-435, October 2005 Heat shock protein 27 interacts with vimentin and prevents insolubilization of vimentin subunits induced by cadmium Jae-Seon Lee1,2*, Mei-Hua Zhang1*, shock protein 27 (HSP27) was colocalized and Eun Kyung Yun1, Dongho Geum3, physically associated with vimentin in unstressed Kyungjin Kim3, Tae-Hyung Kim1, cells, the roles of HSP27 with regard to vimentin were 1 1,4 assessed. HSP27-overexpressing cells prevented Yun-Sook Lim and Jeong-Sun Seo morphological alterations of the vimentin filaments, as well as reductions of soluble vimentin, in the 1ILCHUN Molecular Medicine Institute MRC cadmium-treated cells. Moreover, HSP27 antisense Department of Biochemistry and Molecular Biology oligonucleotide augmented these cadmium-in- Seoul National University College of Medicine duced changes in vimentin. These findings indicate Seoul 110-799, Korea 2 that HSP27 prevents disruption of the vimentin Laboratory of Functional Genomics intermediate filament networks and soluble vimentin Korea Institute of Radiological & Medical Sciences disappearance, by virtue of its physical interaction Seoul 139-706, Korea 3 with vimentin in cadmium-treated SK-N-SH cells. School of Biological Sciences Seoul National University Keywords: apoptosis; cadmium chloride; heat shock Seoul 151-742, Korea protein; mitogen activated protein kinases; molecular 4Corresponding author: Tel, 82-2-740-8246; chaperones; vimentin Fax, 82-2-741-5423; E-mail, [email protected] *These authors contributed equally to this work. Introduction Accepted 26 August 2005 Vimentin is a major component of intermediate fila- Abbreviation: ERK, extracellular signal-regulated kinase; GST, gluta- ment polypeptide, and forms a highly insoluble net- thione S-transferase; HSP, heat-shock protein; JNK, Jun N-terminal work in the fibroblasts.
    [Show full text]
  • Mitochondrial Hsp90 Is a Ligand-Activated Molecular Chaperone Coupling ATP Binding to Dimer Closure Through a Coiled-Coil Intermediate
    Mitochondrial Hsp90 is a ligand-activated molecular chaperone coupling ATP binding to dimer closure through a coiled-coil intermediate Nuri Sunga, Jungsoon Leea, Ji-Hyun Kima,1, Changsoo Changb, Andrzej Joachimiakb, Sukyeong Leea,2, and Francis T. F. Tsaia,c,d,2 aVerna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030; bStructural Biology Center, Biosciences Division, Argonne National Laboratory, Argonne, IL 60439; cDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030; and dDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030 Edited by Manu Sharma, Weill Cornell Medical College, New York, NY, and accepted by the Editorial Board January 28, 2016 (received for review August 14, 2015) Heat-shock protein of 90 kDa (Hsp90) is an essential molecular major role of TRAP1 in tumorigenesis, although TRAP1’sspecific chaperone that adopts different 3D structures associated with function remains poorly understood (28). distinct nucleotide states: a wide-open, V-shaped dimer in the TRAP1 is a multidomain protein consisting of an N-terminal or N apo state and a twisted, N-terminally closed dimer with ATP. domain (TRAP1N), a middle domain (TRAP1M), and a C-terminal Although the N domain is known to mediate ATP binding, how or C domain (TRAP1C), but it lacks the charged linker found Hsp90 senses the bound nucleotide and facilitates dimer closure in eukaryotic Hsp90 paralogs. Human TRAP1 is preceded by a remains unclear. Here we present atomic structures of human mitochondrial localization sequence (MLS) of 59 residues that are cleaved off during import (29).
    [Show full text]
  • Heat Shock Protein 90 Chaperones E1A Early Protein of Adenovirus 5 and Is Essential for Replication of the Virus
    International Journal of Molecular Sciences Article Heat Shock Protein 90 Chaperones E1A Early Protein of Adenovirus 5 and Is Essential for Replication of the Virus Iga Dalidowska 1, Olga Gazi 2, Dorota Sulejczak 1, Maciej Przybylski 2 and Pawel Bieganowski 1,* 1 Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawinskiego 5, 02-106 Warsaw, Poland; [email protected] (I.D.); [email protected] (D.S.) 2 Chair and Department of Medical Microbiology, Medical University of Warsaw, 02-091 Warsaw, Poland; [email protected] (O.G.); [email protected] (M.P.) * Correspondence: [email protected] Abstract: Adenovirus infections tend to be mild, but they may pose a serious threat for young and immunocompromised individuals. The treatment is complicated because there are no approved safe and specific drugs for adenovirus infections. Here, we present evidence that 17-(Allylamino)-17- demethoxygeldanamycin (17-AAG), an inhibitor of Hsp90 chaperone, decreases the rate of human adenovirus 5 (HAdV-5) replication in cell cultures by 95%. 17-AAG inhibited the transcription of early and late genes of HAdV-5, replication of viral DNA, and expression of viral proteins. 6 h after infection, Hsp90 inhibition results in a 6.3-fold reduction of the newly synthesized E1A protein level without a decrease in the E1A mRNA level. However, the Hsp90 inhibition does not increase the decay rate of the E1A protein that was constitutively expressed in the cell before exposure to the inhibitor. The co-immunoprecipitation proved that E1A protein interacted with Hsp90. Altogether, the presented results show, for the first time.
    [Show full text]
  • A Chaperone Network Controls the Heat Shock Response in E. Coli
    Downloaded from genesdev.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press A chaperone network controls the heat shock response in E. coli Eric Guisbert,1 Christophe Herman,2,4,5 Chi Zen Lu,2 and Carol A. Gross2,3,6 Departments of 1Biochemistry and Biophysics, 2Microbiology and Immunology, and 3Stomatology, University of California, San Francisco, San Francisco, California 94143, USA; 4Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA The heat shock response controls levels of chaperones and proteases to ensure a proper cellular environment for protein folding. In Escherichia coli, this response is mediated by the bacterial-specific transcription factor, ␴32. The DnaK chaperone machine regulates both the amount and activity of ␴32, thereby coupling ␴32 function to the cellular protein folding state. In this manuscript, we analyze the ability of other major chaperones in E. coli to regulate ␴32, and we demonstrate that the GroEL/S chaperonin is an additional regulator of ␴32. We show that increasing the level of GroEL/S leads to a decrease in ␴32 activity in vivo and this effect can be eliminated by co-overexpression of a GroEL/S-specific substrate. We also show that depletion of GroEL/S in vivo leads to up-regulation of ␴32 by increasing the level of ␴32. In addition, we show that changing the levels of GroEL/S during stress conditions leads to measurable changes in the heat shock response. Using purified proteins, we show that that GroEL binds to ␴32 and decreases ␴32-dependent transcription in vitro, suggesting that this regulation is direct.
    [Show full text]
  • The Role of Heat Shock Proteins in Regulating Receptor Signal Transduction
    Molecular Pharmacology Fast Forward. Published on January 22, 2019 as DOI: 10.1124/mol.118.114652 This article has not been copyedited and formatted. The final version may differ from this version. MOL # 114652 The Role of Heat Shock Proteins in Regulating Receptor Signal Transduction John M. Streicher, Ph.D. Department of Pharmacology, College of Medicine, University of Arizona, Tucson AZ USA Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 1 Molecular Pharmacology Fast Forward. Published on January 22, 2019 as DOI: 10.1124/mol.118.114652 This article has not been copyedited and formatted. The final version may differ from this version. MOL # 114652 Running Title: Heat Shock Protein Regulation of Receptor Signaling Corresponding Author: Dr. John M. Streicher, Department of Pharmacology, College of Medicine, University of Arizona, Box 245050, LSN563, 1501 N. Campbell Ave., Tucson AZ 85724. Phone: (520)-626-7495. Email: [email protected] Text Pages: 28 Downloaded from Tables: 1 Figures: 1 References: 113 molpharm.aspetjournals.org Abstract: 233 Introduction: 348 Main Text: 3,427 at ASPET Journals on October 2, 2021 Abbreviations: alpha-GDP Dissociation Inhibitor (alpha-GDI); Central Nervous System (CNS); Cyclic Adenosine Monophosphate (cAMP); Cyclin Dependent Kinase (CDK); Extracellular Signal-Regulated Kinase (ERK); Focal Adhesion Kinase (FAK); G Protein-Coupled Receptor (GPCR); G Protein-Coupled Receptor Kinase (GRK); Glycogen Synthase Kinase-3 (GSK-3); Guanosine Di/Triphosphate (GDP/GTP); Heat Shock Factor-1 (HSF-1); Heat shock protein (Hsp); c-Jun N-Terminal Kinase (JNK); Mitogen Activated Protein Kinase (MAPK); MAPK/ERK Kinase (MEK); Protein Kinase A (PKA); Protein Kinase C (PKC); Stress-Induced Phosphoprotein-1 (STIP1); Vascular Endothelial Growth Factor Receptor (VEGFR) 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Targeting the Hsp90-Cdc37-Client Protein Interaction to Disrupt Hsp90 Chaperone Machinery Ting Li1, Hu-Lin Jiang2, Yun-Guang Tong3,4 and Jin-Jian Lu1*
    Li et al. Journal of Hematology & Oncology (2018) 11:59 https://doi.org/10.1186/s13045-018-0602-8 REVIEW Open Access Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery Ting Li1, Hu-Lin Jiang2, Yun-Guang Tong3,4 and Jin-Jian Lu1* Abstract Heat shock protein 90 (Hsp90) is a critical molecular chaperone protein that regulates the folding, maturation, and stability of a wide variety of proteins. In recent years, the development of Hsp90-directed inhibitors has grown rapidly, and many of these inhibitors have entered clinical trials. In parallel, the functional dissection of the Hsp90 chaperone machinery has highlighted the activity disruption of Hsp90 co-chaperone as a potential target. With the roles of Hsp90 co-chaperones being elucidated, cell division cycle 37 (Cdc37), a ubiquitous co-chaperone of Hsp90 that directs the selective client proteins into the Hsp90 chaperone cycle, shows great promise. Moreover, the Hsp90-Cdc37-client interaction contributes to the regulation of cellular response and cellular growth and is more essential to tumor tissues than normal tissues. Herein, we discuss the current understanding of the clients of Hsp90-Cdc37, the interaction of Hsp90-Cdc37-client protein, and the therapeutic possibilities of targeting Hsp90-Cdc37-client protein interaction as a strategy to inhibit Hsp90 chaperone machinery to present new insights on alternative ways of inhibiting Hsp90 chaperone machinery. Keywords: Hsp90 chaperone machinery, Cdc37, Kinase client, Protein interaction Background chloroplast HSP90C, mitochondrial TNFR-associated protein, Heat shock protein 90 (Hsp90) is a critically conserved and bacterial high-temperature protein G [2, 8]. In this protein and one of the major molecular chaperones within review,weusethetermHsp90torefertotheseHsp90 eukaryotic cells [1].
    [Show full text]
  • Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant P53 in Human Cancer Cells
    Published OnlineFirst April 8, 2011; DOI: 10.1158/1541-7786.MCR-10-0534 Molecular Cancer Cancer Genes and Genomics Research Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells Dun Li1, Natalia D. Marchenko1, Ramona Schulz3, Victoria Fischer2, Talia Velasco-Hernandez1, Flaminia Talos1, and Ute M. Moll1,3 Abstract The tight control of wild-type p53 by mainly MDM2 in normal cells is permanently lost in tumors harboring mutant p53, which exhibit dramatic constitutive p53 hyperstabilization that far exceeds that of wild-type p53 tumors. Importantly, mutant p53 hyperstabilization is critical for oncogenic gain of function of mutant p53 in vivo. Current insight into the mechanism of this dysregulation is fragmentary and largely derived from ectopically constructed cell systems. Importantly, mutant p53 knock-in mice established that normal mutant p53 tissues have sufficient enzymatic reserves in MDM2 and other E3 ligases to maintain full control of mutant p53. We find that in human cancer cells, endogenous mutant p53, despite its ability to interact with MDM2, suffers from a profound lack of ubiquitination as the root of its degradation defect. In contrast to wild-type p53, the many mutant p53 proteins which are conformationally aberrant are engaged in complexes with the HSP90 chaperone machinery to prevent its aggregation. In contrast to wild-type p53 cancer cells, we show that in mutant p53 cancer cells, this HSP90 interaction blocks the endogenous MDM2 and CHIP (carboxy-terminus of Hsp70-interacting protein) E3 ligase activity. Interference with HSP90 either by RNA interference against HSF1, the transcriptional regulator of the HSP90 pathway, or by direct knockdown of Hsp90 protein or by pharmacologic inhibition of Hsp90 activity with 17AAG (17-allylamino-17-demethoxygeldanamycin) destroys the complex, liberates mutant p53, and reactivates endogenous MDM2 and CHIP to degrade mutant p53.
    [Show full text]